Last 290.00 GBp
Change Today 0.00 / 0.00%
Volume 0.0
EHP On Other Exchanges
As of 11:35 AM 10/17/14 All times are local (Market data is delayed by at least 15 minutes).

epistem holdings plc (EHP) Snapshot

290.00 GBp
Previous Close
290.00 GBp
Day High
290.00 GBp
Day Low
290.00 GBp
52 Week High
10/25/13 - 340.00 GBp
52 Week Low
10/16/14 - 290.00 GBp
Market Cap
Average Volume 10 Days
-0.16 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for EPISTEM HOLDINGS PLC (EHP)

Related News

No related news articles were found.

epistem holdings plc (EHP) Related Businessweek News

No Related Businessweek News Found

epistem holdings plc (EHP) Details

Epistem Holdings Plc operates as a biotechnology and personalized medicine company commercializing its expertise in epithelial stem cells and infectious disease. The company provides pre-clinical testing, pharmacogenomic biomarker and diagnostic services to the biotechnology and pharmaceutical industries in the United Kingdom and Europe, the United States, and Asia; and develops proprietary molecular tools for the diagnosis of infectious diseases across the world. It operates in three divisions: Preclinical Research Services, Personalised Medicine, and Novel Therapies. The Preclinical Research Services division provides preclinical efficacy testing, immunohistochemistry services, and cell biology expertise in the areas of oncology, oncology supportive care, inflammatory bowel disease, rheumatoid arthritis, and dermatology. The Personalized Medicine division offers sensitive molecular measures of biological processes that enhance precision in drug development, patient stratification and disease treatment. This division discovers, develops, and translates biomarkers for clinical drug development; and offers Genedrive, a molecular diagnostic tool used in bacterial, viral, fungal, and somatic mutational disease identification. The Novel Therapies division is involved in discovering regulators of adult epithelial stem cells and tissues; and developing protein therapeutics that control cell production in the areas of oncology, oncology supportive care, and epithelial diseases. The company was founded in 2000 and is based in Manchester, the United Kingdom.

67 Employees
Last Reported Date: 11/26/13
Founded in 2000

epistem holdings plc (EHP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 300.0K GBP
Co-Founder, Managing Director of Contract Res...
Total Annual Compensation: 104.1K GBP
Chief Financial Officer, Finance Director, Co...
Total Annual Compensation: 130.0K GBP
Compensation as of Fiscal Year 2013.

epistem holdings plc (EHP) Key Developments

EpiStem Holdings Plc Presents at EPIC Biotech 2014, Oct-02-2014 03:00 PM

EpiStem Holdings Plc Presents at EPIC Biotech 2014, Oct-02-2014 03:00 PM. Venue: The King's Fund, 11-13 Cavendish Square, London, W1G 0AN, United Kingdom.

Epistem Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Epistem Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Epistem Holdings Plc Enters into Collaborative Funding Agreement with the Global Health Investment Fund I, LLC

Epistem Holdings Plc announced that it has entered into a collaborative funding agreement with the Global Health Investment Fund I, LLC (GHIF) to support the roll-out of its Genedrive® molecular diagnostic platform as the company's tuberculosis assay enters pivotal field trials in key developing world locations. Under the terms of the agreement, Epistem has issued to the GHIF a five-year convertible bond totaling $8.0 million (GBP 4.7 million) (the Bond). As part of the collaborative funding agreement, the GHIF and Epistem have made global access commitments to mutually support and facilitate the introduction, distribution and sale of the Genedrive® platform and the expanding menu of infectious disease assays under development for low-and middle-income countries. Under the collaborative funding agreement, Epistem has agreed to make its Genedrive® platform available for sale in developing countries under a pricing framework that reflects the needs of poor patients in low- and middle-income countries. The GHIF will seek to leverage its network to support Epistem in the final stages of clinical testing and regulatory approval, and the subsequent roll-out of Genedrive® and its infectious disease assays globally. The Genedrive® platform has the potential to dramatically improve the lives of those most at risk of diseases such as tuberculosis, which require sophisticated diagnostic techniques to identify the presence of the disease and prescribe the proper course of treatment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EHP:LN 290.00 GBp 0.00

EHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EHP.
View Industry Companies

Industry Analysis


Industry Average

Valuation EHP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.3x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPISTEM HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at